Literature DB >> 22239151

Genetic association of FOXP3 gene polymorphisms with allograft rejection in renal transplant patients.

Xiao-Yan Qiu1, Zheng Jiao, Ming Zhang, Jian-Ping Chen, Xiao-Jin Shi, Ming-Kang Zhong.   

Abstract

AIM: FOXP3 gene is known to be important for regulatory T cell development and function, and is associated with the rejection of human kidney transplants. The present study was therefore conducted to determine the effect of FOXP3 polymorphisms on allograft rejection in renal transplant recipients.
METHODS: A total of 166 adult patients were categorized into either a Rejection group (65 patients) or a No rejection group (101 patients). Rs3761547, rs3761548 and rs2232365 variant alleles in the FOXP3 gene were genotyped using a TaqMan probe technique, and their relationships with rejection were investigated.
RESULTS: There was no significant difference in the genotype frequencies of rs3761547 and rs2232365 variants between patients with and without rejection history (P > 0.05). Binary logistic regression analysis showed that the rs3761548 AA genotype carriers were associated with about a fourfold greater risk for rejection compared with CC genotype (5 years post-transplant: odds ratio 3.95, 95% confidence interval 1.27-12.29, P = 0.018). Kaplan-Meier analysis revealed a lower mean time to the first rejection in rs3761548 AA compared with CC genotype patients (Log rank = 4.303, P = 0.038). Multivariate Cox regression analysis indicated that rs3761548 AA genotype carriers have up to about a twofold (hazard ratio 2.37, 95% confidence interval 1.17-4.80, P = 0.017) higher risk for rejection than CC carriers.
CONCLUSION: Our study suggests an association between FOXP3 rs3761548 polymorphisms and allograft rejection in renal transplantation. This association should be further proven in large prospective studies because of the small sample size and confounding factors in this retrospective study.
© 2012 The Authors. Nephrology © 2012 Asian Pacific Society of Nephrology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22239151     DOI: 10.1111/j.1440-1797.2012.01561.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  6 in total

1.  FOXP3 rs3761548 polymorphism is associated with tacrolimus-induced acute nephrotoxicity in renal transplant patients.

Authors:  Zhuo Wu; Qinxia Xu; Xiaoyan Qiu; Zheng Jiao; Ming Zhang; Mingkang Zhong
Journal:  Eur J Clin Pharmacol       Date:  2016-10-17       Impact factor: 2.953

2.  The rs3761548 FOXP3 variant is associated with multiple sclerosis and transforming growth factor β1 levels in female patients.

Authors:  Tamires Flauzino; Daniela Frizon Alfieri; Wildea Lice de Carvalho Jennings Pereira; Sayonara Rangel Oliveira; Ana Paula Kallaur; Marcell Alysson Batisti Lozovoy; Damacio Ramón Kaimen-Maciel; Karen Brajão de Oliveira; Andrea Name Colado Simão; Edna Maria Vissoci Reiche
Journal:  Inflamm Res       Date:  2019-08-14       Impact factor: 4.575

3.  Significant association between FOXP3 gene polymorphism and steroid-resistant acute rejection in living donor liver transplantation.

Authors:  Sapana Verma; Yuka Tanaka; Seiichi Shimizu; Naoki Tanimine; Hideki Ohdan
Journal:  Hepatol Commun       Date:  2017-06-08

4.  Association of Foxp3 Polymorphism With Allograft Outcome in Kidney Transplantation.

Authors:  Hyewon Park; Nuri Lee; Ji Won In; Eun Youn Roh; Kyoung Un Park; Sue Shin; Jaeseok Yang; Eun Young Song
Journal:  Ann Lab Med       Date:  2017-09       Impact factor: 3.464

5.  Association of FOXP3 Single Nucleotide Polymorphisms With Clinical Outcomes After Allogenic Hematopoietic Stem Cell Transplantation.

Authors:  Minjeong Nam; Sue Shin; Kyoung Un Park; Inho Kim; Sung Soo Yoon; Tack Kyun Kwon; Eun Young Song
Journal:  Ann Lab Med       Date:  2018-11       Impact factor: 3.464

6.  Polymorphisms in mTOR and Calcineurin Signaling Pathways Are Associated With Long-Term Clinical Outcomes in Kidney Transplant Recipients.

Authors:  Antony Brayan Campos-Salazar; Fabiana Dalla Vecchia Genvigir; Claudia Rosso Felipe; Helio Tedesco-Silva; José Medina-Pestana; Gabriela Vieira Monteiro; Rodrigo de Gouveia Basso; Alvaro Cerda; Mario Hiroyuki Hirata; Rosario Dominguez Crespo Hirata
Journal:  Front Pharmacol       Date:  2018-11-14       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.